期刊文献+

新型截短侧耳素衍生物的合成及抗菌活性研究 被引量:1

Synthesis and biological evaluation of novel pleuromutilin derivatives with nitrogen-containing heterocycles as antibacterial agents
原文传递
导出
摘要 通过将含氮杂环与WL001的2-氨基噻唑侧链相连,设计合成了一系列新的截短侧耳素衍生物。用革兰阳性和革兰阴性菌对该系列化合物进行体外抗菌活性测定,合成的大多数化合物不仅在药物敏感菌株中表现出抗菌活性,而且在耐药菌株中也有相同效果。特别值得注意的是具有饱和氮杂环的化合物表现出显著的抗菌活性(0.062 5~8μg·m L-1),优于或类似于阿莫西林、泰妙菌素和左氧氟沙星。此外,15a和15b含有哌啶或吗啉的化合物同样能够有效的抑制革兰阴性菌。本研究为相关截短侧耳素衍生物的设计提供了一个新视野,为进一步研究治疗耐药性致病菌奠定了基础。 A series of new pleuromutilins derivatives were designed and synthesized through coupling 2-aminothiazole ring of WL001 with different nitrogen-containing substituted heterocycles in the side chain. Their biological activities were evaluated against both Gram-positive and Gram-negative clinical bacteria in vitro Most new compounds displayed specificity to certain strain of bacteria. Particularly, compounds with saturated nitrogen-containing heterocycles exhibited significant antibacterial activities (0.062 5-8 μg·mL-1) superior or similar to those of amoxicillin, tiamulin and levofloxcin. Furthermore, treatment with 15a and 15b having piperidine or morpholine residues also could effectively inhibit Gram-negative bacteria. Therefore, our novel findings may provide a new insight into the design of novel pleuromutilin derivatives and lay the basis for further studies on the treatment of drug-resistance of pathogenic bacteria
出处 《药学学报》 CAS CSCD 北大核心 2015年第10期1297-1304,共8页 Acta Pharmaceutica Sinica
基金 江苏省自然科学基金资助项目(BK2011389) 南通市科技局科技项目(BK2012093) 南通大学自然科学基金资助项目(07Z086)
关键词 截短侧耳素衍生物 抗菌活性 含氮杂环化合物 耐药的革兰阳性病原体 pleuromutilin derivative antibacterial activity nitrogen-containing heterocycle resistantGram-positive pathogen
  • 相关文献

参考文献2

二级参考文献111

  • 1Infectious Diseases Society of America. The 10 x' 20 initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020 [J]. Clin Infect Dis, 2010, 50:1081-1083.
  • 2Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America [J]. Clin Infect Dis, 2009, 48:1-12.
  • 3Rice LB. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE [J]. J Infect Dis, 2008, 197: 1079-1081.
  • 4Arias CA, Murray BE. Antibiotic-resistant bugs in the 21st century - a clinical super-challenge [J]. N Engl J Med, 2009, 360: 439-443.
  • 5Hvistendahl M. China takes aim at rampant antibiotic resistance [J]. Science, 2012, 336: 795.
  • 6Yezli S, Li H. Antibiotic resistance amongst healthcare- associated pathogens in China [J]. Int J Antimicrob Agents, 2012, 40: 389-397.
  • 7Taubes C The bacteria fight back [J]. Science, 2008, 321: 356-361.
  • 8Tortes C. Up against wall [J]. Nat Med, 2010, 16: 628-631.
  • 9Silver LL. Challenges of antibacterial discovery [J]. Clin Microbiol Rev, 2011, 24:71-109.
  • 10Coates A, Hu Y, Bax R, et al. The future challenges facing the development of new antimicrobial drugs [J]. Nat Rev Drug Discov, 2002, 1 : 895-910.

共引文献19

同被引文献4

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部